Himalaya is committed to bettering lives by delivering effective, safe and differentiated cancer therapies to patients
Himalaya was founded with the exclusive rights from BioAtla to develop and commercialize several specific CAB candidates for the Greater China market of the PRC, Hong Kong, Macau and Taiwan, including two Phase 1/2 clinical stage assets, as well as worldwide rights to two additional preclinical drug candidates
Himalaya is a rapidly growing company of world class, experienced teams driving the company to success for patients in greater China.
Himalaya is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide. The company has exclusive rights to deploy CAB antibodies in its territories, with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively. CAB antibodies are focused on addressing life-threatening, unmet medical needs in cancer treatment.
Our strategic approach is to manage and coordinate drug development from lead to IND to market through our internal capabilities as well as through leading contract providers and strategic partners. The ability to access transformative products at the lead stage from BioAtla, allows the company to reduce risk by focusing on drug development without sacrificing innovation.
For more information, contact us here**